Aytu BioScience, Inc, a specialty healthcare company focused on developing treatments for urological and related conditions, has acquired  Jazz Pharmaceuticals’ rights to ProstaScint, an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the US.

ProstaScint’s established brand and revenue will enable Aytu to expand its footprint in urology and advance its pipeline of therapeutics and diagnostics.

Josh Disbrow, chief executive officer of Aytu BioScience, stated “We are delighted to expand our portfolio of urology-focused products with ProstaScint. This product acquisition demonstrates our core business strategy and commitment to building a portfolio of late-stage and revenue-generating assets. We expect the revenue from ProstaScint to help drive our clinical development and accelerate the growth of this newly formed specialty healthcare company.”

Aytu recently completed a reverse merger that incorporated the pipeline assets Zertane, a first-in-class treatment for premature ejaculation (PE) that is nearing commercial-stage, and the RedoxSYS System, which has CE Marking for Europe and medical device approval by Health Canada, from Vyrix Pharmaceuticals and Luoxis Diagnostics, respectively.

ProstaScint is a murine monoclonal antibody conjugated to a linker-chelator that targets Prostate Specific Membrane Antigen (PSMA), a glycoprotein expressed by the prostate epithelium. The product has been marketed in the US since 1997.